New era of early cancer detection blood tests on the horizon

Dr Deb Schrag speaks to ecancer about PATHFINDER, a prospective study of a multi-cancer early detection blood test.
A validated blood-based multi-cancer early detection (MCED) test uses cfDNA and machine learning to detect a common cancer signal across over 50 cancer types and where the signal is coming from. PATHFINDER is a prospective study in a screening population that evaluated the clinical feasibility of MCED testing.
The study, reported at the ESMO Congress 2022, is the first prospective investigation to show that an MCED test can detect cancer in patients with undiagnosed cancer, as previous studies used tests only in patients already known to have cancer.
A number of further studies are now underway including a major randomised clinical trial enroling 140,000 asymptomatic people in England to investigate the clinical effectiveness of MCED testing on cancer outcomes.

[@DistractedAlly]

So how many individuals were tested total and how many had new cancer detected? I am welcome to new information though. Please present links to these followings, so I may keep up.

[@DistractedAlly]

This has provided no new information.